IRIS
FERRARA, ROBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.563
EU - Europa 2.272
NA - Nord America 1.665
SA - Sud America 305
Continente sconosciuto - Info sul continente non disponibili 149
AF - Africa 35
AN - Antartide 1
OC - Oceania 1
Totale 7.991
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 2.066
US - Stati Uniti d'America 1.532
RU - Federazione Russa 1.253
CN - Cina 577
IT - Italia 402
HK - Hong Kong 370
RO - Romania 266
BR - Brasile 251
BD - Bangladesh 221
VN - Vietnam 172
FR - Francia 98
CA - Canada 56
GB - Regno Unito 56
MX - Messico 44
DE - Germania 41
IN - India 29
NL - Olanda 29
AR - Argentina 21
PL - Polonia 20
TR - Turchia 20
SE - Svezia 18
AT - Austria 17
ZA - Sudafrica 17
ES - Italia 16
FI - Finlandia 13
ID - Indonesia 13
IQ - Iraq 12
LT - Lituania 12
JP - Giappone 11
UA - Ucraina 11
JM - Giamaica 9
CO - Colombia 8
PK - Pakistan 8
SA - Arabia Saudita 8
AE - Emirati Arabi Uniti 7
EC - Ecuador 7
MY - Malesia 6
PH - Filippine 6
TT - Trinidad e Tobago 6
VE - Venezuela 6
NP - Nepal 5
CR - Costa Rica 4
CZ - Repubblica Ceca 4
DZ - Algeria 4
GT - Guatemala 4
IE - Irlanda 4
KZ - Kazakistan 4
MA - Marocco 4
NI - Nicaragua 4
UY - Uruguay 4
UZ - Uzbekistan 4
AZ - Azerbaigian 3
ET - Etiopia 3
IL - Israele 3
JO - Giordania 3
TH - Thailandia 3
BE - Belgio 2
BH - Bahrain 2
BO - Bolivia 2
CH - Svizzera 2
HN - Honduras 2
OM - Oman 2
PE - Perù 2
PT - Portogallo 2
PY - Paraguay 2
TW - Taiwan 2
AL - Albania 1
AQ - Antartide 1
BA - Bosnia-Erzegovina 1
BJ - Benin 1
BZ - Belize 1
CI - Costa d'Avorio 1
CL - Cile 1
CY - Cipro 1
DO - Repubblica Dominicana 1
EG - Egitto 1
GD - Grenada 1
GR - Grecia 1
HU - Ungheria 1
IR - Iran 1
KE - Kenya 1
KH - Cambogia 1
KR - Corea 1
LV - Lettonia 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
PS - Palestinian Territory 1
RS - Serbia 1
SC - Seychelles 1
SR - Suriname 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
TN - Tunisia 1
Totale 7.842
Salva come PNG Salva come JPEG
Città #
Hong Kong 366
Singapore 306
San Jose 290
Moscow 268
Ashburn 193
Beijing 156
Dallas 136
Council Bluffs 123
New York 98
Hefei 96
Milan 82
Lauterbourg 80
Ho Chi Minh City 60
Santa Clara 59
Los Angeles 57
Rome 54
Hanoi 27
Mexico City 25
São Paulo 24
Denver 21
Orem 19
Montreal 17
Chicago 16
Florence 15
Naples 15
Buffalo 14
Pasadena 14
Toronto 14
Warsaw 14
Houston 13
Munich 13
Phoenix 13
Brooklyn 12
Manchester 12
Shanghai 12
Vienna 12
Da Nang 11
Stockholm 11
Bologna 10
Johannesburg 10
Omaha 10
Rio de Janeiro 10
Ankara 9
Cesano Boscone 9
Haiphong 9
Poplar 9
Boardman 8
Boston 8
Chennai 8
Falkenstein 8
Helsinki 8
Tokyo 8
Amsterdam 7
Brescia 7
Nuremberg 7
Tianjin 7
Assago 6
Brasília 6
Catania 6
Figino 6
Frankfurt am Main 6
Guangzhou 6
Hangzhou 6
Kyiv 6
London 6
Seattle 6
Tampa 6
Bari 5
Can Tho 5
Goiânia 5
Iesi 5
Istanbul 5
Kingston 5
Porto Alegre 5
Querétaro 5
Riyadh 5
Rotherham 5
Verona 5
Adams Center 4
Baghdad 4
Barnet 4
Bogotá 4
Calgary 4
Campinas 4
Changsha 4
City of London 4
Dhaka 4
Knoxville 4
Kuala Lumpur 4
Las Vegas 4
Managua 4
Miami 4
Milwaukee 4
Parma 4
Shenzhen 4
Tashkent 4
Turin 4
Venice 4
Washington 4
Aalsmeer 3
Totale 3.128
Salva come PNG Salva come JPEG
Nome #
Autoantibody positivity predicts severity of rheumatic immune-related adverse events to immune-checkpoint inhibitors 395
Exploring machine learning tools in a retrospective case-study of patients with metastatic non-small cell lung cancer treated with first-line immunotherapy: A feasibility single-centre experience 236
Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers 225
Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI) 198
Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system 194
Genomics and Immunomics in the Treatment of Urothelial Carcinoma 193
Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Non-small Cell Lung Cancer 192
Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake 188
OncoAlert Round Table Discussions: The Global COVID-19 Experience 183
High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors 169
Facing the First-line in Metastatic Non-small-cell Lung Cancer – Immunotherapy and Chemotherapy 167
Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice 162
Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series 121
Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC 115
RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion 109
ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations 103
Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies 102
Sex dimorphism and cancer immunotherapy: May pregnancy solve the puzzle? 100
Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171) 94
Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D 93
Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer 93
Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program 91
DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non-Small-Cell Lung Cancer: An External Validation 91
Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer 90
Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic Progression 89
Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLC 84
Prognostic value of histogram analysis in advanced non-small cell lung cancer: a radiomic study 83
Myeloid cell heterogeneity in lung cancer: implication for immunotherapy 83
Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology 83
Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study 81
Hyperprogressive disease: recognizing a novel pattern to improve patient management 81
CD8+PD-1+ to CD4+PD-1+ ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers 79
Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Non-Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or Chemotherapy 78
Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer 78
An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer 74
Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer 74
Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria 72
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers-Letter 72
Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer 72
Benefits and Harms of Lung Cancer Screening by Chest Computed Tomography: A Systematic Review and Meta-Analysis 71
Adjuvant therapy for resected early-stage small-cell lung cancer: is now time to rethink about that? 69
A Case of William's Syndrome in a Ugandan Child: A Feasible Diagnosis Even in a Low-Resource Setting 68
Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non-Small Cell Lung Cancer 66
Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out 66
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial 66
Atypical patterns of response and progression in the era of immunotherapy combinations 65
Adenosine Pathway in NSCLC With Molecular Drivers: Can Oncogene Addiction Translate Into Immune Addiction? 65
EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort 65
SMO mutations confer poor prognosis in malignant pleural mesothelioma 65
Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non‐small‐cell lung cancer and EGFR mutation 65
Immune checkpoint inhibitors versus second line chemotherapy for patients with lung cancer refractory to first line chemotherapy 65
Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors 65
Characterization of patients with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapy 63
Immunotherapy 62
Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors 62
Evaluation of Drug-Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors 62
Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer 60
Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer 59
Human virome profiling identified CMV as the major viral driver of a high accumulation of senescent CD8+ T cells in patients with advanced NSCLC 57
Acquired hemophagocytic syndrome in a patient with synovial sarcoma: a case report 57
Modulation of PD-1/PD-L1 axis in myeloid-derived suppressor cells by anti-cancer treatments 56
Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: young oncologists' perspective 56
Stereotatic radiotherapy in metastatic non-small cell lung cancer: Combining immunotherapy and radiotherapy with a focus on liver metastases 54
Clinical and Translational Implications of RET Rearrangements in Non-Small Cell Lung Cancer 54
Circulating T-cell Immunosenescence in Patients with Advanced Non-small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy 54
The Prognostic Role of TNM Staging Compared With Tumor Volume and Number of Pleural Sites in Malignant Pleural Mesothelioma 53
Shifting From a "One Size Fits All" to a Tailored Approach for Immune-Related Adverse Events 53
Circulating innate immune markers and outcomes in treatment-naïve advanced non-small cell lung cancer patients 52
Diagnosis and treatment of early and locally advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines 51
Progress in the Management of Advanced Thoracic Malignancies in 2017 51
Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors 51
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy 51
Do immune checkpoint inhibitors need new studies methodology? 50
Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress? 49
Unexpected Huge Prevalence of Intracardiac Extension of Wilms Tumor—A Single Center Experience from a Ugandan Hospital 48
Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer 48
The development of PARP as a successful target for cancer therapy 48
Wide and Cystic Brain Metastases Reveal RET-Rearranged Non-Small-Cell Lung Cancers 47
Machine Learning Using Real-World and Translational Data to Improve Treatment Selection for NSCLC Patients Treated with Immunotherapy 47
Immune checkpoint inhibitors and chemotherapy in first-line NSCLC: a meta-analysis 47
Tubulin inhibitors in non-small cell lung cancer: looking back and forward 46
The Anti–Programmed Cell Death Protein-1/ Programmed Death-Ligand 1 Me-Too Drugs Tsunami: Hard To Be Millennials Among Baby Boomers 44
The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives 43
Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients 42
How to recognize and manage hyper-progression and pseudo-progression during immune checkpoint blockade in non-small cell lung cancer 42
Hyperprogression-Immunotherapy-Related Phenomenon vs Intrinsic Natural History of Cancer-In Reply 41
Pseudoprogression in Non-Small Cell Lung Cancer upon Immunotherapy: Few Drops in the Ocean? 41
The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies 41
Immune checkpoint inhibitors for non-small-cell lung cancer: does that represent a 'new frontier'? 41
Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: Does age really matter? 40
Novel patterns of progression upon immunotherapy in other thoracic malignancies and uncommon populations 40
Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines 40
Clarification of Definitions of Hyperprogressive Disease During Immunotherapy-Reply 36
Is hyperprogressive disease a specific phenomenom of immunotherapy? 33
Robotic Surgery Is a Safe Treatment in Very Elderly Patients with Resectable Lung Cancer 32
Multidisciplinary management of N2 stage III non-small cell lung cancer: opportunities and challenges for radiation oncology 26
Blinded independent central review versus local investigator assessment of PFS in RCTs of immunotherapy in advanced cancers: A systematic review and meta-analysis 22
A viable human lung cancer tissue collection (LCTC) to accelerate translational research 21
Neoadjuvant vs perioperative chemo-immunotherapy according to pathological response in resectable non-small cell lung cancer: A reconstructed individual patient data meta-analysis 10
APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research 10
Totale 7.941
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.038
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.038
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222 0 0 2 0 0 0 0 0 0 0 0 0
2022/202314 3 2 1 0 0 1 1 2 0 0 2 2
2023/202440 2 4 2 2 2 5 6 3 3 3 1 7
2024/20252.532 16 6 1 6 9 7 404 66 214 300 761 742
2025/20264.780 383 308 146 440 413 170 417 321 1.282 300 251 349
2026/2027623 268 355 0 0 0 0 0 0 0 0 0 0
Totale 7.991